AbbVie hands Voyager a mega-billions gene therapy deal, with $310M in near-term cash
Gene therapy company Voyager Therapeutics has kicked off 2019 in style. After forging an up to $1.8 billion pact with Neurocrine last month, the Parkinson’s drug developer expanded its partnership with AbbVie on Friday, days following the anniversary of their original pact.
Basic subscription required
Unlock this story instantly and join 54,600+ biopharma pros reading Endpoints daily — and it's free.